March « 2016 « Science and Enterprise

Regeneron, Bayer Collaborating on Eye Disorder Drug

By Alan, on March 24th, 2016%

(Public Domain Pictures, Pixabay)

24 March 2016. Regeneron Pharmaceuticals and drug-maker Bayer AG are developing a combination of biologic drugs to treat the eye disorders wet age-related macular degeneration and diabetic macular edema. The agreement — the third such deal between the companies — is expected to bring Regeneron as much as $130 . . . → Read More: Regeneron, Bayer Collaborating on Eye Disorder Drug

Propeller, Boehringer Partner on Inhaler Adherence Study

By Alan, on March 23rd, 2016%

(Tradimus, Wikiimedia Commons)

23 March 2016. The pharmaceutical company Boehringer Ingelheim is collaborating with a mobile health technology developer to track use of its medications for asthma and COPD administered with its inhaler. Financial aspects of the agreement between Propeller Health in Madison, Wisconsin, and Boehringer Ingelheim were not disclosed.

Boehringer Ingelheim, headquartered . . . → Read More: Propeller, Boehringer Partner on Inhaler Adherence Study

New Biotech Begins Work on Enhanced Platinum Cancer Drugs

By Alan, on March 23rd, 2016%

(National Cancer Institute)

23 March 2016. A new biotechnology company began work today on developing improved platinum-based treatments for solid tumor cancers. The company, Placon Therapeutics in Cambridge, Massachusetts, is a spin-off enterprise from Tarveda Therapeutics, a developer of biologic cancer drugs.

Placon Therapeutics focuses on new treatments for cancer using platinum as . . . → Read More: New Biotech Begins Work on Enhanced Platinum Cancer Drugs

Quick Tests for Mosquito-Borne Viruses Being Developed

By Alan, on March 22nd, 2016%

(Public Domain Pictures/Pixabay)

22 March 2016. A Canadian company is developing diagnostic tests that it says can detect in 1 minute antibodies in blood indicating the early-stage presence of Zika and other mosquito-borne viruses. The company bioLytical Laboratories in Richmond, British Columbia says its proof-of-concept studies show the feasibility of these quick, point-of-care . . . → Read More: Quick Tests for Mosquito-Borne Viruses Being Developed

Nanoparticles Shown to Target Tumors, Avoid Adjacent Cells

By Alan, on March 22nd, 2016%

Drug nanoparticle illustration (National Cancer Institute)

22 March 2016. A small-scale clinical trial shows cancer drugs formulated into nanoparticles accumulate in solid tumors in humans, while avoiding adjacent healthy tissue. The team from California Institute of Technology in Pasadena published its findings yesterday (21 March) in the journal Proceedings of the National Academy . . . → Read More: Nanoparticles Shown to Target Tumors, Avoid Adjacent Cells

23andMe Creates Research Software for iPhone Apps

By Alan, on March 21st, 2016%

(JEShoots, Pixabay)

21 March 2016. The personal genetics company 23andMe wrote a software module for Apple’s ResearchKit platform that makes it possible to add genetics data to iPhone apps used in medical research. The module, says 23andMe, in Mountain View, California, also supports genetics data from other sources, with three research apps now . . . → Read More: 23andMe Creates Research Software for iPhone Apps

Merck Licensing Harvard Cancer Drug Molecules

By Alan, on March 21st, 2016%

Matthew Shair (Stephanie Mitchell, Harvard University)

21 March 2016. The pharmaceutical company Merck is licensing small molecule research discoveries from a Harvard University lab as potential treatments for leukemia. The agreement brings the university $20 million immediately, with further payments expected as Merck develops the discoveries into products.

The deal gives Merck an . . . → Read More: Merck Licensing Harvard Cancer Drug Molecules

Cancer Diagnostics Company Raises $12.3M in IPO

By Alan, on March 18th, 2016%

(A. Kotok)

18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced . . . → Read More: Cancer Diagnostics Company Raises $12.3M in IPO

Implant Developed to Deliver Alzheimer’s Immunotherapy

By Alan, on March 18th, 2016%

Brain wiring illustration (Courtesy, Human Connectome Project and NIH)

18 March 2016. A neuroscience team from Ecole polytechnique fédérale de Lausanne, or EPFL, in Switzerland designed and implanted a capsule that in lab mice generates antibodies to reduce amyloid beta plaque accumulations in the brain associated with Alzheimer’s disease. Researchers from the lab . . . → Read More: Implant Developed to Deliver Alzheimer’s Immunotherapy

Allied-Bristol Licenses NYU Research, Starts New Company

By Alan, on March 17th, 2016%

NYU medical center (nyu.edu)

17 March 2016. Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb, is licensing research from New York University on signaling pathways affecting growth of tumors, for a new company begun under its tutelage. Financial aspects of the deal between Allied-Bristol and NYU were not disclosed.

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise